PBMC-Tumor Cell Co-Culture Cytotoxicity Platform: Bridging the Gap in Immune In Vitro Cytotoxicity Studies

Welcome to our PBMC-Tumor Cell Co-Culture Cytotoxicity Platform, a cutting-edge tool for studying immune-mediated cell killing in an in vitro environment. This platform employs a combination of peripheral blood mononuclear cells (PBMCs) and tumor cells co-cultured together. By utilizing CSFE-labeled tumor cells and CD45-labeled immune cells, we can distinguish effector cells from target cells, allowing us to validate the cytotoxicity of target cells using flow cytometry. This innovative approach minimizes the impact of immune cell proliferation and apoptosis on the test results.

Key Features and Advantages:

Precise Cytotoxicity Assessment: Our platform enables precise assessment of cytotoxicity by separating effector cells (immune cells) from target cells (tumor cells). This segregation is facilitated by the use of CSFE and CD45 markers, ensuring accurate measurements of cell killing.

Flow Cytometry Validation: We employ flow cytometry to validate the level of cytotoxicity exerted by immune cells on tumor cells. This technology provides detailed insights into the interaction between immune cells and tumor cells, allowing for quantitative analysis of cytotoxic effects.

Mitigation of Non-Specific Activation: Our platform can detect non-specific activation of immune cells, such as CD3, CD28, and IL-2 activation of T cells. This capability allows us to differentiate between specific and non-specific immune responses, providing a comprehensive view of immune cell activity.

Enhanced Research Relevance: By mimicking the immune-mediated cytotoxicity observed in vivo, our platform offers a more physiologically relevant model for studying immune responses to tumors. This is essential for the development and evaluation of immunotherapies.

Applications:

Our PBMC-Tumor Cell Co-Culture Cytotoxicity Platform has wide-ranging applications, including:

Immunotherapy Development: Assessing the cytotoxic potential of immune cells against tumor cells is crucial for the development of effective immunotherapies.

Drug Screening: Evaluating the impact of potential drugs or compounds on immune-mediated cytotoxicity, aiding in drug discovery.

Immunology Research: Gaining insights into the mechanisms of immune cell killing and understanding how non-specific activation influences immune responses.

Personalized Medicine: Tailoring treatments based on individual patient immune responses to improve therapeutic outcomes.

Our platform offers a unique opportunity to study immune-mediated cytotoxicity with precision and relevance. If you have any questions or would like to explore how our platform can support your research or drug development efforts, please do not hesitate to contact us. We look forward to collaborating with you to advance the field of immune-mediated cytotoxicity studies.

Cytotoxicity evaluation of patient primary tumor cells and PBMCs co-culture - in vitro efficacy assessment of immunotherapy
Experimental procedure：

Case: In vitro detection of PD-1 efficacy on clinical colorectal cancer and ovarian cancer patients.